Objective To study the clinical value of combined detection of serum pepsinogenⅠ,Ⅱ(PGⅠ, PGⅡ) and gastrin-17 (G-17) in the diagnosis of gastric cancer. Methods One hundred and four patients with gastric disease checked in our hospital were selected as study objects. The patients were divided into four groups:gastric can-cer group (29 cases), atrophic gastritis group (30 cases), gastrohelcosis group (24 cases), and superficial gastritis group (21 cases). Moreover, 20 healthy individuals were enrolled as control group. A fixed volume (3 ml) of blood sample was obtained from each patient, then separated for serum and kept in-20℃refrigerator. The serum levels of PGⅠ, PGⅡ, G-17 were detected by using ELISA. Results (1) The serum level of PGⅠwere significantly lower in gastric cancer group and atrophic gastritis group than the control group (P<0.05), and also lower in gastric cancer group than atrophic gastritis group. The level in gastrohelcosis group was significantly higher than all the other groups. The differ-ences above were all statistically significant (P<0.05). There was no significant difference in the PGⅠlevel between superficial gastritis group and the control group (P>0.05). G-17 level in the gastric cancer group was significantly higher than all the other groups, and the level in atrophic gastritis group was significantly lower than all the other groups (P<0.05). There was no statistically significant difference in the level of PGⅡ between the five groups (P>0.05). (2) The area under the receiver operating characteristic curve of combined detection of PGⅠand G-17 in gas-tric cancer group was 0.976, higher than single detection of PGⅠ(0.895) and G-17 (0.918). (3) Logistic regression equation was P=1/[1+e-(-5.421-0.079 PGI+0.845 G-17)]. Diagnosis of point was P=0.1271. Diagnostic sensitivity and specificity of combined detection of PGⅠand G-17 were 0.966 and 0.900. Conclusion Combined detection of PGⅠand G-17 could increase the diagnostic rate of gastric cancer, which might have important clinical significant for the early diag-nosis of gastric cancer.%目的：探讨血清胃蛋白酶原Ⅰ、Ⅱ(PGⅠ、PGⅡ)、胃泌素-17(G-17)联合检测在胃癌早期诊断中的临床价值。方法选择我院经胃镜检查确诊的104例胃疾病患者为研究对象，以组织病理学检查结果将受检者分为4组，即胃癌组29例、萎缩性胃炎组30例、胃溃疡组24例、浅表性胃炎组21例。同时从我院体检中心选择经胃镜检查无任何异常的20例作为对照组。各组均在胃镜检查前抽取空腹静脉血3 ml，分离血清，-20℃冰箱保存。采用ELISA法检测PGⅠ、PGII、G-17。结果(1)胃癌组和萎缩性胃炎组血清PGⅠ水平显著低于健康对照组，胃癌组血清PGⅠ水平又明显低于萎缩性胃炎组；而胃溃疡组与其他各组相比血清PGⅠ水平明显增高；以上差异均有统计学意义(P<0.05)。浅表性胃炎组与健康对照组的血清PGⅠ水平比较差异无统计学意义(P>0.05)。胃癌组血清G-17水平明显高于其他各组，而萎缩性胃炎组明显低于其他各组，差异均有统计学意义(P<0.05)；各组血清PGⅡ水平差异均无统计学意义(P>0.05)。(2) PGⅠ、G-17单独或联合检测结果作胃癌诊断的ROC分析，线下面积分别为0.895、0.918、0.976。(3) Logistic回归方程为P=1/[1+e-(-5.421-0.079 PGⅠ+0.845 G-17)]。诊断点P=0.1271，敏感性为0.966，特异性为0.900。结论血清PGⅠ及G-17联合检测可提高胃癌诊断率，对胃癌早期诊断具有重要的临床意义。
展开▼
